The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

David P. Steensma

Mayo Clinic

Rochester

MN 55905

USA

[email]@mayo.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Mayo Clinic, Rochester, MN 55905, USA. 2000 - 2009
  • Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. 2009
  • Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, USA. 2001 - 2009
  • Department of Medicine (Hematology) and Oncology, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA. 2006
  • MRC Molecula Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, United Kingdom. 2004
  • Department of Internal Medicine, Division of Hematology, West 10, Mayo Clinic Rochester, USA. 2001 - 2003

References

  1. Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes. Steensma, D.P., Neiger, J.D., Porcher, J.C., Keats, J.J., Bergsagel, P.L., Dennis, T.R., Knudson, R.A., Jenkins, R.B., Santana-Davila, R., Kumar, R., Ketterling, R.P. Cancer Res. (2009) [Pubmed]
  2. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. Steensma, D.P., Baer, M.R., Slack, J.L., Buckstein, R., Godley, L.A., Garcia-Manero, G., Albitar, M., Larsen, J.S., Arora, S., Cullen, M.T., Kantarjian, H. J. Clin. Oncol. (2009) [Pubmed]
  3. Myelodysplasia paranoia: iron as the new radon. Steensma, D.P. Leuk. Res. (2009) [Pubmed]
  4. Erythropoiesis-stimulating agents are effective in myelodysplastic syndromes, but are they safe?. Steensma, D.P. Am. J. Hematol. (2009) [Pubmed]
  5. The Blood of the Lamb. Steensma, D.P. J. Clin. Oncol. (2009) [Pubmed]
  6. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Steensma, D.P., Heptinstall, K.V., Johnson, V.M., Novotny, P.J., Sloan, J.A., Camoriano, J.K., Niblack, J., Bennett, J.M., Mesa, R.A. Leuk. Res. (2008) [Pubmed]
  7. Investment analysts and the American Society of Hematology. Steensma, D.P. Blood (2008) [Pubmed]
  8. The art of oncology: when the tumor is not the target. Don't mention it. Steensma, D.P. J. Clin. Oncol. (2008) [Pubmed]
  9. The mosaic of myeloid neoplasia: implications for classification. Steensma, D.P. Leuk. Lymphoma (2008) [Pubmed]
  10. Risk-based management of myelodysplastic syndrome. Steensma, D.P., Tefferi, A. Oncology (Williston Park, N.Y.) (2007) [Pubmed]
  11. Candidate gene mutation analysis in idiopathic acquired sideroblastic anemia (refractory anemia with ringed sideroblasts). Steensma, D.P., Hecksel, K.A., Porcher, J.C., Lasho, T.L. Leuk. Res. (2007) [Pubmed]
  12. Prevalence of erythrocyte haemoglobin H inclusions in unselected patients with clonal myeloid disorders. Steensma, D.P., Porcher, J.C., Hanson, C.A., Lathrop, C.L., Hoyer, J.D., Lasho, T.A., Tefferi, A., Higgs, D.R. Br. J. Haematol. (2007) [Pubmed]
  13. Exacerbation of asthma by Florida "red tide" during an ocean sailing trip. Steensma, D.P. Mayo Clin. Proc. (2007) [Pubmed]
  14. A history of the kidney in plasma cell disorders. Steensma, D.P., Kyle, R.A. Contrib. Nephrol (2007) [Pubmed]
  15. Anemia in the elderly: how should we define it, when does it matter, and what can be done?. Steensma, D.P., Tefferi, A. Mayo Clin. Proc. (2007) [Pubmed]
  16. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony. Steensma, D.P. J. Support. Oncol (2007) [Pubmed]
  17. The myelodysplastic syndromes: diagnosis and treatment. Steensma, D.P., Bennett, J.M. Mayo Clin. Proc. (2006) [Pubmed]
  18. Are myelodysplastic syndromes "cancer"? Unexpected adverse consequences of linguistic ambiguity. Steensma, D.P. Leuk. Res. (2006) [Pubmed]
  19. Luis Walter Alvarez: another "Mayo-trained" Nobel Laureate. Steensma, D.P. Mayo Clin. Proc. (2006) [Pubmed]
  20. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. Steensma, D.P., Molina, R., Sloan, J.A., Nikcevich, D.A., Schaefer, P.L., Rowland, K.M., Dentchev, T., Novotny, P.J., Tschetter, L.K., Alberts, S.R., Hogan, T.F., Law, A., Loprinzi, C.L. J. Clin. Oncol. (2006) [Pubmed]
  21. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Steensma, D.P., McClure, R.F., Karp, J.E., Tefferi, A., Lasho, T.L., Powell, H.L., DeWald, G.W., Kaufmann, S.H. Leukemia (2006) [Pubmed]
  22. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. Steensma, D.P. J. Mol. Diagn (2006) [Pubmed]
  23. MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count. Steensma, D.P., Caudill, J.S., Pardanani, A., McClure, R.F., Lasho, T.L., Tefferi, A. Haematologica (2006) [Pubmed]
  24. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Steensma, D.P., Gibbons, R.J., Mesa, R.A., Tefferi, A., Higgs, D.R. Eur. J. Haematol. (2005) [Pubmed]
  25. Does treatment with recombinant human erythropoietin affect the survival of anemic patients with cancer?. Steensma, D.P., Witzig, T.E. Nature Clinical Practice. Oncology (2005) [Pubmed]
  26. Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations. Steensma, D.P., Higgs, D.R., Fisher, C.A., Gibbons, R.J. Blood (2004) [Pubmed]
  27. Management of anemia in patients with cancer. Steensma, D.P. Curr. Oncol. Rep (2004) [Pubmed]
  28. Reassurance. Steensma, D.P. J. Clin. Oncol. (2004) [Pubmed]
  29. Northwoods elegy. Steensma, D.P. Ann. Intern. Med. (2004) [Pubmed]
  30. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Steensma, D.P., Dispenzieri, A., Moore, S.B., Schroeder, G., Tefferi, A. Blood (2003) [Pubmed]
  31. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Steensma, D.P., Tefferi, A. Leuk. Res. (2003) [Pubmed]
  32. Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?. Steensma, D.P., Dewald, G.W., Hodnefield, J.M., Tefferi, A., Hanson, C.A. Leuk. Res. (2003) [Pubmed]
  33. The kiss of death: a severe allergic reaction to a shellfish induced by a good-night kiss. Steensma, D.P. Mayo Clin. Proc. (2003) [Pubmed]
  34. "Pawn Ball Megakaryocytes": from the marvellous medici and dear Old Saint Nick to the unsanctified marrow of myelodysplasia. Steensma, D.P. Hematology (2003) [Pubmed]
  35. The narrow path. Steensma, D.P. J. Clin. Oncol. (2003) [Pubmed]
  36. Submitting to autonomy. Steensma, D.P. J. Clin. Oncol. (2003) [Pubmed]
  37. Why me?. Steensma, D.P. J. Clin. Oncol. (2003) [Pubmed]
  38. Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome. Steensma, D.P., Tefferi, A., Li, C.Y. Leuk. Res. (2003) [Pubmed]
  39. The chronic myeloproliferative disorders: an historical perspective. Steensma, D.P. Curr. Hematol. Rep. (2003) [Pubmed]
  40. Why me?. Steensma, D.P. J. Clin. Oncol. (2002) [Pubmed]
  41. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Steensma, D.P., Mesa, R.A., Li, C.Y., Gray, L., Tefferi, A. Blood (2002) [Pubmed]
  42. Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. Steensma, D.P., Hook, C.C., Stafford, S.L., Tefferi, A. Br. J. Haematol. (2002) [Pubmed]
  43. "Congo" red: out of Africa?. Steensma, D.P. Arch. Pathol. Lab. Med. (2001) [Pubmed]
  44. Hereditary red blood cell disorders in middle eastern patients. Steensma, D.P., Hoyer, J.D., Fairbanks, V.F. Mayo Clin. Proc. (2001) [Pubmed]
  45. The narrow path. Steensma, D.P. J. Clin. Oncol. (2001) [Pubmed]
  46. Myelodysplasia with fibrosis: a distinct entity?. Steensma, D.P., Hanson, C.A., Letendre, L., Tefferi, A. Leuk. Res. (2001) [Pubmed]
  47. Myelodysplastic syndrome and pregnancy: the Mayo Clinic experience. Steensma, D.P., Tefferi, A. Leuk. Lymphoma (2001) [Pubmed]
  48. Hydroxyurea-associated platelet count oscillations in polycythemia vera: a report of four new cases and a review. Steensma, D.P., Harrison, C.N., Tefferi, A. Leuk. Lymphoma (2001) [Pubmed]
  49. Submitting to autonomy. Steensma, D.P. J. Clin. Oncol. (2000) [Pubmed]
 
WikiGenes - Universities